S. Ramotar

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature

F. Notta, S. Gallinger, R. Denroche, 2021, Journal of Clinical Pathology.

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

R. Khokha, F. Notta, J. Bartlett, 2020, Clinical Cancer Research.

Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

C. Moulton, S. Gallinger, R. Jang, 2022, World journal of gastroenterology.

Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

F. Notta, S. Gallinger, R. Denroche, 2021 .

Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma

R. Khokha, F. Notta, S. Gallinger, 2023, British Journal of Cancer.

Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy.

F. Notta, S. Gallinger, R. Denroche, 2020 .

Outcomes and Immunogenicity of pancreatic cancer stratified by the HRDetect score.

F. Notta, S. Gallinger, R. Denroche, 2020 .

hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma (PDAC).

F. Notta, S. Gallinger, R. Denroche, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.